Dr. Christopher David Corso, MD

Dr. Corso practices at Southeast Radiation Oncology Group, P.A. in Charlotte, North Carolina.

Dr. Corso's NPI, 1871868026, was assigned on March 20, 2012. Dr. Corso graduated from Emory University School of Medicine in 2012. Dr. Corso holds North Carolina license 2017-00143.

Dr. Corso's primary practice is Southeast Radiation Oncology Group, P.A., at 200 Queens Rd, Charlotte, NC 28204 in Mecklenburg County. The practice phone is (704) 333-7376.

Dr. Corso's primary practice is Southeast Radiation Oncology Group, P.A. in Charlotte, North Carolina. Dr. Corso is also affiliated with Atrium Health Carolinas Medical Center. The medical group on file is SERO (Southeast Radiation Oncology Group). Dmand AI also links Dr. Corso to 3 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Corso practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Corso's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Corso's licenses on file in 2 states: North Carolina and South Carolina.

CMS data shows 3,150 Medicare services from Dr. Corso across 20 procedure codes in 2024, for 310 Medicare patients. Medicare paid $242,936 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 310 Medicare patients who saw Dr. Corso in 2024. The largest group is 65 to 74, with 139 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Corso's median patient age at 74, with 47% women.

In 2024, Dr. Corso wrote 212 Medicare Part D claims for 113 patients. 94% of them were for generic drugs. CMS names the drug for 128 of them, across 5 drugs with 11 or more claims each, at $3,068 in total drug cost. In 2023, CMS named 141 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Corso for performance year 2024, reported through an alternative payment model (APM). Dr. Corso accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Corso as offering telehealth.

Dmand AI links 9 papers to Dr. Corso, published from 2017 to 2024. 2019 was the busiest year, with 2. The most frequent topics are Radiosurgery, Brain Neoplasms and Carcinoma, Non-Small-Cell Lung. Dr. Corso's most frequent co-authors are Stuart Heinrich Burri, MD, Roshan Sudhir Prabhu, MD and John Henry Heinzerling, MD.

CMS Open Payments shows 15 general payments to Dr. Corso from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Elekta, Inc. paid the most, $2,088.

Dr. Corso graduated from Emory University School of Medicine in 2012.